A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas - PubMed

Affiliations

• PMID: 29582423
• DOI: 10.1002/ijc.31404

A PRDX1-p38α heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas

Peter Wirthschaft et al. Int J Cancer. 2018.

Abstract

The Peroxiredoxin 1 (PRDX1) gene maps to chromosome arm 1p and is hemizygously deleted and epigenetically silenced in isocitrate dehydrogenase 1 or 2 (IDH)-mutant and 1p/19q-codeleted oligodendroglial tumors. In contrast, IDH-wildtype astrocytic gliomas including glioblastomas mostly lack epigenetic silencing and express PRDX1 protein. In our study, we investigated how PRDX1 contributes to the infiltrative growth of IDH-wildtype gliomas. Focusing on p38α-dependent pathways, we analyzed clinical data from 133 patients of the NOA-04 trial cohort to look for differences in the gene expression profiles of gliomas with wildtype or mutant IDH. Biochemical interaction studies as well as in vitro and ex vivo migration studies were used to establish a biological role of PRDX1 in maintaining pathway activity. Whole-brain high-resolution ultramicroscopy and survival analyses of pre-clinical mouse models for IDH-wildtype gliomas were then used for in vivo confirmation. Based on clinical data, we found that the absence of PRDX1 is associated with changes in the expression of MET/HGF signaling components. PRDX1 forms a heterodimer with p38α mitogen-activated protein kinase 14 (MAPK14), stabilizing phospho-p38α in glioma cells. This process amplifies hepatocyte growth factor (HGF)-mediated signaling and stimulates actin cytoskeleton dynamics that promote glioma cell migration. Whole-brain high-resolution ultramicroscopy confirms these findings, indicating that PRDX1 promotes glioma brain invasion in vivo. Finally, reduced expression of PRDX1 increased survival in mouse glioma models. Thus, our preclinical findings suggest that PRDX1 expression levels may serve as a molecular marker for patients who could benefit from targeted inhibition of MET/HGF signaling.

Keywords: c-MET; gliomas; invasion; p38α; peroxiredoxin 1.

Similar articles

• c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.

  Ohba S, Yamada Y, Murayama K, Sandika E, Sasaki H, Yamada S, Abe M, Hasegawa M, Hirose Y. Ohba S, et al. World Neurosurg. 2019 Jun;126:e1042-e1049. doi: 10.1016/j.wneu.2019.03.040. Epub 2019 Mar 13. World Neurosurg. 2019. PMID: 30878754

• Methylation-mediated miR-155-FAM133A axis contributes to the attenuated invasion and migration of IDH mutant gliomas.

  Huang GH, Du L, Li N, Zhang Y, Xiang Y, Tang JH, Xia S, Zhang EE, Lv SQ. Huang GH, et al. Cancer Lett. 2018 Sep 28;432:93-102. doi: 10.1016/j.canlet.2018.06.007. Epub 2018 Jun 6. Cancer Lett. 2018. PMID: 29885519

• CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.

  Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D; POLA Network. Appay R, et al. Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124. Neuro Oncol. 2019. PMID: 31832685 Free PMC article.

• Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.

  Malzkorn B, Reifenberger G. Malzkorn B, et al. Pathologe. 2019 Jun;40(Suppl 1):9-17. doi: 10.1007/s00292-019-0581-8. Pathologe. 2019. PMID: 31025086 Review. English.

• [Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version].

  Malzkorn B, Reifenberger G. Malzkorn B, et al. Pathologe. 2019 Mar;40(2):131-139. doi: 10.1007/s00292-019-0575-6. Pathologe. 2019. PMID: 30790013 Review. German.

Cited by

• Mesenchymal Epithelial Transition Factor Signaling in Pediatric Nervous System Tumors: Implications for Malignancy and Cancer Stem Cell Enrichment.

  Khater AR, Abou-Antoun T. Khater AR, et al. Front Cell Dev Biol. 2021 May 13;9:654103. doi: 10.3389/fcell.2021.654103. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34055785 Free PMC article. Review.

• Identification of an IFN-β-associated gene signature for the prediction of overall survival among glioblastoma patients.

  Cheng L, Yuan M, Li S, Lian Z, Chen J, Lin W, Zhang J, Zhong S. Cheng L, et al. Ann Transl Med. 2021 Jun;9(11):925. doi: 10.21037/atm-21-1986. Ann Transl Med. 2021. PMID: 34350240 Free PMC article.

• In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor.

  Ariey-Bonnet J, Carrasco K, Le Grand M, Hoffer L, Betzi S, Feracci M, Tsvetkov P, Devred F, Collette Y, Morelli X, Ballester P, Pasquier E. Ariey-Bonnet J, et al. Mol Oncol. 2020 Dec;14(12):3083-3099. doi: 10.1002/1878-0261.12810. Epub 2020 Oct 18. Mol Oncol. 2020. PMID: 33021050 Free PMC article.

• Large-scale characterization of the microvascular geometry in development and disease by tissue clearing and quantitative ultramicroscopy.

  Hahn A, Bode J, Alexander A, Karimian-Jazi K, Schregel K, Schwarz D, Sommerkamp AC, Krüwel T, Abdollahi A, Wick W, Platten M, Bendszus M, Tews B, Kurz FT, Breckwoldt MO. Hahn A, et al. J Cereb Blood Flow Metab. 2021 Jul;41(7):1536-1546. doi: 10.1177/0271678X20961854. Epub 2020 Oct 12. J Cereb Blood Flow Metab. 2021. PMID: 33043767 Free PMC article.

• BIRB796, an Inhibitor of p38 Mitogen-Activated Protein Kinase, Inhibits Proliferation and Invasion in Glioblastoma Cells.

  Zhao L, Wang Y, Xu Y, Sun Q, Liu H, Chen Q, Liu B. Zhao L, et al. ACS Omega. 2021 Apr 22;6(17):11466-11473. doi: 10.1021/acsomega.1c00521. eCollection 2021 May 4. ACS Omega. 2021. PMID: 34056302 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • scite Smart Citations

• Miscellaneous

  • NCI CPTAC Assay Portal